var data={"title":"Society guideline links: Plasma cell dyscrasias","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Society guideline links: Plasma cell dyscrasias</div><p class=\"disclosureLink\"></p><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H4082612137\"><span class=\"h1\">Introduction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.</p><p>The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.</p><p class=\"headingAnchor\" id=\"H2722319216\"><span class=\"h1\">International</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30189-4/fulltext&amp;token=rxmI5XY2r+qPNKyQ7LM+to7G1A7f3tJDDfHCprW0fps3iYW3qhPGVC5k6T6gcMsmeS/99N/oBKEHAyHPVjxyuLIbo0RiTq/B4FruiE0pX1xUexfzF0dpXg+kdwUWJiF0&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">International Myeloma Working Group (IMWG): A consensus statement on the role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/bjh.14492/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKSBtjF4IFtG098sfOfLm7rGft/6NhMHMNY/AEziFAH1QQ==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">International Workshops on Waldenstr&ouml;m Macroglobulinaemia (IWWM): Consensus panel recommendations for investigation and management of IgM and Waldenstr&ouml;m-associated peripheral neuropathies</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1002/cyto.b.21249/epdf&amp;token=iklU5b+iNYhKWTz+5OTqoee+b14YQHPbwS2joDQ18lN04CJmnD4W+1/bso32fsipp+chWhvOQpTwNw7BUvEODELf+TaqXctC0kDgnRYQPvc=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">International Clinical Cytometry Society (ICCS): Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition, 2015</a> (published 2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1002/cyto.b.21228/epdf&amp;token=brcDS0+122MVhq/WLyMKwVLWcMYd8G+z01hCqIKhkCGWAW0zbtLj2ZPUgn2YLxjcklUyjcuklw8CVUdsHB5nB6B2QoYtPnZ+1YTjUIgLR5s=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">ICCS: Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting, 2015</a> (published 2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.bloodjournal.org/content/bloodjournal/127/24/2955.full.pdf&amp;token=dP1xGjeZhmfvfB7SwDZ4pVQqT2Q9gPbDKvHppLqCCvrr/H3ZjjIENv4zGwUJO9Veaqp2L9tZAaZX9vHihlcOuJiAYLbC1Vnt5Hm6JdD+K1U=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: A consensus on treatment of multiple myeloma with high-risk cytogenetics</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30206-6/fulltext?rss=yes&amp;token=b74KMnS25pzQ+TBtxyJJe7qGgG/WtuhIO5pmlskuJt6LFjFfMG4LdbnvBobkqAaW1rf5/xkKz/y4SG56iIZq6vV1y6sTTUCzem5lhXRUHsuAE5AjTC8MU6PRPILS2FR1&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Consensus criteria for response and minimal residual disease assessment in multiple myeloma</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://ascopubs.org/doi/pdf/10.1200/JCO.2015.65.0044&amp;token=aJ9UZTaRmXCaYkPY9N2/psiBLZZKohV47wT0nmVCDq1VArf+9s09/YjIhenPnDMQdqK0s2Wfr6Hn53mNydgGXA==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Recommendations for the diagnosis and management of myeloma-related renal impairment</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.bbmt.org/article/S1083-8791(15)00641-2/pdf&amp;token=Fr01suG0rrd7MMoYQUh6lPq2CVJ9uxItJV9Iq3vtlK+E67pqRrOw8kiHbqyVeX8frd88QY2JIw678LwUKGlHHA==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">American Society of Blood and Marrow Transplantation (ASBMT), European Society of Blood and Marrow Transplantation (EBMT), Blood and Marrow Transplant Clinical Trials Network (BMTCTN), and IMWG: Guidelines on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma</a> (2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://ascopubs.org/doi/pdf/10.1200/JCO.2014.57.9961&amp;token=aJ9UZTaRmXCaYkPY9N2/psiBLZZKohV47wT0nmVCDq0LlVAe7/wvFi+8db8uziSeF8PtqO6TXAwM3xfhjLbh/A==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: A consensus statement on the role of magnetic resonance imaging in the management of patients with multiple myeloma</a> (2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.nature.com/leu/journal/v30/n5/full/leu2015356a.html?foxtrotcallback=true&amp;token=3AmoBZQdOQkHTrG44a+79BOZQ3OE5YI96qWJxXEVzbstwr2KUpnv+ignkxoKPBQ2C4h27X38XkeqlSyO/t39FU0vp3m6ya+5EtJw6irzlIbQE78Fq8bpP+/p2w57uDvK&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Recommendations for management of relapsed multiple myeloma</a> (2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.myeloma.org/sites/default/files/images/research/2014_leukemia-_chng-_imwg_consensus_on_risk_stratification_in_mm.pdf&amp;token=3Aw6GrWuI5JaPMtkRmsJPtTVIuwMkwvZHL2WSPZ4GiWh3eyZiEcJf4hbRpCNWUwjRPs+GdJppF2WqD2sv6vdSj9G/OnZsMreEptPfnTAdEkPIIVJGDKptgIU7R/qA4hEOm7SVI1e+mP3Dj0R4XYGhA==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Consensus on risk stratification in multiple myeloma</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.myeloma.org/sites/default/files/images/research/2014_jco-_palumbo-_imwg_consensus_statement_for_management_treatment_supportive_care.pdf&amp;token=Pa4k4P6cz31Cpb5bNrzpQB/uaOgLorL22Xsbg0xaJulOykYOubT2akRGSsRRSRoORsmDrlBHbWp4iFi5wdqgcIrIVulzsyVAWB9R4ZcM/7OysPAbrnzhMISvksYH/Ji7oKTgbxpsMtOj3iwLVSnWGybvgU+r0P/CTXAE05jElMU=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(14)70442-5.pdf&amp;token=T4slFgMKaJb+0Y4X17ZdcqvEIsYm5fdWmrm/Bk2ZYKpNJiXIB9JLCbObpoXv/yyl+EX9Wrsov8pQLcPy6/ZeCmfSB57YHOVa/MBQGrg4avqvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Criteria for the diagnosis of multiple myeloma, update</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.myeloma.org/sites/default/files/images/research/imwg_pcl_fernandez_de_larrea_2013.pdf&amp;token=6h2SOCkYtJcsKCXH/hJsbho387eOqFnJHJqKMiK9DVTCYmIeOJW5oOljQnv16k++oqrXhblnm48A3KG9ftrxZJNkC0xhoJlARLlIKPaWQeAR2jPWKW9N07fBCK7Sq9hs&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Consensus statement on diagnostic requirements, response criteria and treatment recommendations for plasma cell leukemia</a> (2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.myeloma.org/sites/default/files/images/research/2013_leukemia-_ludwig-_imwg_recommendations_for_global_myeloma_care.pdf&amp;token=aZTo1BbF/YcxyaAiEaEU72cLffdUd94eci081CHZyAfZVecdl5xh6J/51qIF3qWDjpc0JuB5SdX0bDCKqIEmlJKv3Kq6x44Tt+KyQHou2ZmaT4BBMKebLLzhiL/3wYSXqnnCQSwvag7HuGawojuJxw==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Recommendations for global myeloma care</a> (2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.myeloma.org/sites/default/files/images/research/imwgtreatment_of_mm_related_bone_disease.pdf&amp;token=BOiJYaH+Fx55JyNRmyWB2Fb07pgUyNRAYQJc1mYfcp2O8qImroVZvkZ+uzX63Mh49SnGXvLxKFk8CsJJU7rrjUF1a2isJBUn+2KDZtUUpG6iB06zb7soo1roq3eWq+nr&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Recommendations for the treatment of multiple myeloma&ndash;related bone disease</a> (2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(13)70404-2.pdf&amp;token=T4slFgMKaJb+0Y4X17ZdcqvEIsYm5fdWmrm/Bk2ZYKpNJiXIB9JLCbObpoXv/yylcvLz8Nq03w4G8IF4TwUaTfr3K3koEB9nPEDMgG60MkuvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Resource-stratified guidelines for management of multiple myeloma in Asia</a> (2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.myeloma.org/sites/default/files/images/research/blood-2012-ludwig.pdf&amp;token=WDmlVMiT5PfC8CGM+mRnlWu4cjTys20H5s3yK+bCe/hkYNRDoWe/S/WV0NPc/JQFBoom6MnlP20ByT5DK172tDRrUh0utUPWabsZcJ/P/Vc=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Consensus on maintenance therapy in multiple myeloma</a> (2012)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.myeloma.org/sites/default/files/images/research/blood-2011-cavo.pdf&amp;token=swThPz65pQMTv8PDitwB8LJYc1gAnowSo4ysXG+Jep2ySWQd4nj0d4LJxssAlj9Yur2eGYpLS4vMKWSgRgBiKAiYNurC4LLjxx0LkJkPpsU=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation</a> (2011)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.myeloma.org/sites/default/files/images/research/management_of_pn.pdf&amp;token=CaOyN0O3ftLEZffzqG4LtL0ipO7cgX+ah15v5To8C19d0XSUiXGy7Z+8lzbzd+vZccpVB+o6srydnVRE5prvuKY5Z/08Aho+yT8dIMm/pAQ=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Management of treatment-emergent peripheral neuropathy in multiple myeloma</a> (2011)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.myeloma.org/sites/default/files/images/research/2010-leukemia-kyle-mgus_and_smoldering_mm._imwg_perspectives.pdf&amp;token=Q10CWCHhp8XlERfj5f3cf5sNC/Ei5/pCj7WyDfNJR1+k8XVu+tKCgB4gRAqaGgajqJkBVnD5894sVQI6jSzzhLjqNj/IN1WUp1OQsneOXOx69Uewu+ojLR5pjvtS3mxVCj1pP6lPwLl+aW0f0vHG1A==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Consensus perspective risk factors for progression and guidelines for monitoring and management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma</a> (2010)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.myeloma.org/sites/default/files/images/research/imwg_plerixafor.pdf&amp;token=PWoAVd2LGNh0HHFhySY/tWbXbpNlPT4npAKyZp/VQ3EZudKupRzVFBIdPr4PuzRk98QHIqhC6Bfpx9VolA/QgCANDuf9H0g6age1afPtVmA=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)</a> (2009)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.myeloma.org/sites/default/files/images/research/blood_06_29_09_kumar.pdf&amp;token=lKSk2lGOZy9SeA21tqpwZa4FUmFxNQVQHepYbc1lUri1yF+i6pPxS5M1835ZzxClyYJZ8lMoHmIiajbf8rrsxOzLqwqIIUl0GnrVZHEyQUS5YZiLPIYQrNR0YVe9Vo2b&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Mobilization in myeloma revisited &ndash; Consensus perspectives on stem cell collection following initial therapy with thalidomide, lenalidomide or bortezomib-containing regimens</a> (2009)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.myeloma.org/sites/default/files/images/research/2009-leukemia-imwg-molecular.pdf&amp;token=ECMNyLqlCFnq/IGgIrDAqhLQOAHJsGH47ZDDu5Owzk8kyi33I6RiGD1ItYc7JVWR1Q2nARszr+rFc8icPjMatvLx4HRHxkFmHgwQZ+6xUgXB45+NQ4QJt+bYQOBc8vE6&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Spotlight review on molecular classification of multiple myeloma</a> (2009)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.myeloma.org/sites/default/files/images/research/imwg_consensusguidelinesvertebralaugmentation.pdf&amp;token=T5A++bBTmQxJ9LE8xqod5E+fas0Wq3KT6mPz18svZHx5F3HIknrdeoiXcuvDeX0VE5ontEAet/+Ndi1bjUQ9kNyX1q1UjAQdlRYMoEbolh3zljBJ7bgO4hGfcSRaMYwQ&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Consensus statement on the role of vertebral augmentation in multiple myeloma</a> (2008)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.myeloma.org/sites/default/files/images/research/imwf_flc_guidelines_leukemia2008.pdf&amp;token=8GYbkGNp+nEqaMhgWwTtTYtPzR8W8GUW5lUnzMWbDmiOH8Ki2/HPaTPPU4PU/3PrAvvYHDsDnMWGWzn8LriiL3md1uXntcP/H0KWO0HdM6Ms3dcHRA3jFxVCb59B7IeX&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Guidelines for serum-free light chain analysis in multiple myeloma and related disorders</a> (2008)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.myeloma.org/sites/default/files/images/research/dvtguidelinesdec2007.pdf&amp;token=8D7JJ2PU9PUuHSozGVrx/to7zA/zIDQWxneS/0UMmM3VL//i1rDm6D9/Cp/2wL9R9+UeTTC6SG8hZMwo7xVCkcVhSU6Yo+pn/2tPowo7mHevALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">IMWG: Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma</a> (2008)</p><p/><p class=\"headingAnchor\" id=\"H3121633521\"><span class=\"h1\">Canada</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34323&amp;token=R4Uiw8/bmPVaqNHRDqpXLOtUvb7WjbUcvgwNrHP/L96ybiTF4gLHhIQ+sguai0NWuwE0WLWQKdhBcrUiUS3hVLQ1YstSwy5A6IqRY6BFMzs=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">Cancer Care Ontario (CCO): Evidence-based series on bortezomib in multiple myeloma and leukemia</a> (2013, reviewed 2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=137819&amp;token=R4Uiw8/bmPVaqNHRDqpXLOtUvb7WjbUcvgwNrHP/L96ybiTF4gLHhIQ+sguai0NWMN0pGqDRMDCeMpVqRoU770xlI6QL+K0rBVmi1guA1UE=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">CCO: Evidence-based series on lenalidomide in multiple myeloma</a> (2012, reviewed 2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/986&amp;token=1HBRTEgtaV4FEdIrVTLjhfHGkbOwdjhRaGzfWTvb8kzO6MQjXt6gNr+LkT5T03u2SjMzuwGZOLb85MUKK0t7rZ7RxqE+NeFsV0OLOqAaD9Q=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">CCO: Recommendation report on stem cell transplantation in multiple myeloma</a> (2012)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/981&amp;token=Oha0scMVXciLLW504U7jsvHGkbOwdjhRaGzfWTvb8kzO6MQjXt6gNr+LkT5T03u2SjMzuwGZOLb85MUKK0t7rep/AS4KMDrjolUqDxWjBFk=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">CCO: Recommendation report on stem cell transplantation in primary systemic amyloidosis</a> (2012)</p><p/><p class=\"headingAnchor\" id=\"H1797798641\"><span class=\"h1\">United States</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://ascopubs.org/doi/pdf/10.1200/JCO.2017.76.6402&amp;token=aJ9UZTaRmXCaYkPY9N2/psiBLZZKohV47wT0nmVCDq1A7AbaqgbEpJ7u30WcJpJd7iXuL424Fert8TUEkSm/Eg==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">American Society of Clinical Oncology (ASCO): Clinical practice guideline on the role of bone-modifying agents in multiple myeloma, 2017 update</a> (published 2018)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf&amp;token=YmN5bdGskeARRXAlM0vZ/W7kZBd8i5cfl/XXh/hkJBFuJm0UrhRrOsRAlE1K9HNneAGl8C/g4klNz04CdbLa/9NcmvZCnOtRj8JoERaM3ns=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">National Comprehensive Cancer Network (NCCN): Clinical practice guidelines in oncology &ndash; Multiple myeloma</a> (2018)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf&amp;token=LLV/3V8UBXRLKMr/+nKWyW0cLLezf8RWMoIw/S2faawEG4lZmxQkgPP5AaZhfdl1ZWioS6rRCgd/HHYOH97HTypIrtkTOdmyyIxTGLIfyFc=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">NCCN: Clinical practice guidelines in oncology &ndash; Waldenstr&ouml;m's macroglobulinemia/lymphoplasmacytic lymphoma</a> (2018)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nccn.org/professionals/physician_gls/pdf/amyloidosis.pdf&amp;token=DGvvZht6vUG0190BNanfVgvilftvd5cYFrP6vbDfdk5HD1tff+RvPCf/zV/4OdvRzaMssDLLA2W5gDR+OVxjEvPJBRgsUWeaHrZ8PbpFLRc=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">NCCN: Clinical practice guidelines in oncology &ndash; Systemic light chain amyloidosis</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://jitc.biomedcentral.com/track/pdf/10.1186/s40425-016-0188-z?site=jitc.biomedcentral.com&amp;token=0c43woUiCJYpb0PzWCpWj4iTxAWTJoe2WF8CwSElTraUp+DTCJodyHVVjm6TsohtMKIEspGizMUqf2U5OHCi28Vkn+nXO1jcG8ovgJ1cUqI=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">Society for Immunotherapy of Cancer (SITC): Consensus statement on immunotherapy for the treatment of hematologic malignancies &ndash; Multiple myeloma, lymphoma, and acute leukemia</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://asbmt.org/sites/default/files/asbmt_admin/HSCT_for_Multiple_Myeloma_-_.pdf&amp;token=94RYBJBq+FjwgOK+iLhT8fu6ak0atA/pdDKbqSQJKXbLq70Qo+mKHowFdAV6nlqv5JZ8e4uoyvP9s9sRLM60tFvtD1X7pnu8mTrAlGPd2rCDqfE1ov/scToxF4WQphEN&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">American Society of Blood and Marrow Transplantation (ASBMT): Guidelines on hematopoietic stem cell transplantation for multiple myeloma</a> (2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.bbmt.org/article/S1083-8791(15)00641-2/pdf&amp;token=Fr01suG0rrd7MMoYQUh6lPq2CVJ9uxItJV9Iq3vtlK+E67pqRrOw8kiHbqyVeX8frd88QY2JIw678LwUKGlHHA==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">ASBMT, European Society of Blood and Marrow Transplantation (EBMT), Blood and Marrow Transplant Clinical Trials Network (BMTCTN), and International Myeloma Working Group (IMWG): Guidelines on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma</a> (2015)</p><p/><p class=\"headingAnchor\" id=\"H1774363305\"><span class=\"h1\">Europe</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.esmo.org/Guidelines/Haematological-Malignancies/Multiple-Myeloma&amp;token=BThq9Fz2uNslSv0NAcI6aExaTvKQalxY2WMmdJblO4gC0OcdEiZAmyBblGCm0WLYrKy6os2ru1o+fmgWg9cY+CLyRFU2v/UmU57IqYjhjvY=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">European Society for Medical Oncology (ESMO): Clinical practice guidelines for diagnosis, treatment and follow-up of multiple myeloma</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.bbmt.org/article/S1083-8791(15)00641-2/pdf&amp;token=Fr01suG0rrd7MMoYQUh6lPq2CVJ9uxItJV9Iq3vtlK+E67pqRrOw8kiHbqyVeX8frd88QY2JIw678LwUKGlHHA==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">American Society of Blood and Marrow Transplantation (ASBMT), European Society of Blood and Marrow Transplantation (EBMT), Blood and Marrow Transplant Clinical Trials Network (BMTCTN), and International Myeloma Working Group (IMWG): Guidelines on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma</a> (2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://academy.myeloma.org.uk/wp-content/uploads/sites/2/2017/11/EMN-maangement-of-myeloma-related-conditions.pdf&amp;token=oEg8n3Wbb+ngOoUvpm8itCo1po2Zonw/mJy2dNkfSpq50d04KHfbpjIMU58TJSB2VTD1CfGHYYEFpnSxmeA+7ithQ1IZGj4L78KZAEdlqI7z7gto6UsUR0heE2J98olbKcRercQ/l19FsyuyiagmIA==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">European Myeloma Network (EMN): Guidelines for the management of multiple myeloma-related complications</a> (2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://academy.myeloma.org.uk/wp-content/uploads/sites/2/2014/08/Managemnet-of-MGUS-and-related-disorders-2014.pdf&amp;token=R3ldyVhM1OfMoTn6Q+V8dr9ZYNotOHWQoa/z/bclz38mzSAOxuu0nvGwS+blq6fGBjLLGakkD5fOOskUIsCG4mH3kROmzKqPSUzCV99Vz0KSoAvcA/8JK2EUP/BZzI64EcnNp9H54LIegPVTpSimAw==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">EMN: Recommendations on the clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://academy.myeloma.org.uk/wp-content/uploads/sites/2/2014/08/Evaluation-and-tx-of-NDMM-2014.pdf&amp;token=Ns2VY6szYKurY4VXUpeyeCWyUVAXi0seB4vJkKXNqn4f9yBSdk5G6RdqW9yWOSp60yiyH86pXVkRCPEVq05px2zZpIxDS3u7RKW8TVPBzv4IrhJ/qWcJAbQ9tAJveA+Qp2iZgurodm6oG+gaJkqPkA==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">EMN: Recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma, 2013</a> (published 2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.esmo.org/Guidelines/Haematological-Malignancies/Waldenstrom-s-Macroglobulinaemia&amp;token=yDh/quk4esRkRrQnTVTtCr0Pxj8K3wBF35LsiImTZABm4B/nH+xhzRDQMorxMPebwjmFolotY0gXRSUu/ba3ucVZTnX3UK9qVeBFqJj3CXE8OJjZblaN5Low4ThnJ0ro&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">ESMO: Clinical practice guidelines for diagnosis, treatment and follow-up of Waldenstr&ouml;m's macroglobulinaemia</a> (2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nature.com/articles/leu20113.pdf&amp;token=wEsKVFvqlKzpT+qOtddW/x+fYTQTJ/LoY1NfuyJYKglqTO8JfBG6l1+wgq9e83vrDd/T0UoKhrqtdehd4l8Gdw==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">EMN: Consensus statement on optimizing the use of lenalidomide in relapsed or refractory multiple myeloma</a> (2011)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1529-8027.2010.00278.x/abstract&amp;token=0Ec5EOitvXznLEgKDnljuOeJksKPd9IyfiDopYhsk9lO2wiMRIujQlqBY/GJ5T0QybxcxxGQtvsTgNkMBXcRnsHsjmIPvYOxC8tKhnVLJHM=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">European Federation of Neurological Societies (EFNS)/Peripheral Nerve Society (PNS): Guideline on management of paraproteinemic demyelinating neuropathies &ndash; First revision</a> (2010)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://academy.myeloma.org.uk/wp-content/uploads/sites/2/2014/08/EMN-Bisphosphonate-guidelines.pdf&amp;token=eKmgZuEXyqN6aY2UiB+pyBI3BPKZQyOTpiiQ2ywhSWDuz7rH5uY+VvkobibgDnh6+r2LQnB7hTSPu7d5ih6zSDmCfN3zH9x4EL8tVAdAmlPdK5qB7pIsSQeFQnfzd2tLsy/LxmQYoGgZ3uMCAGl6QA==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">EMN: Recommendations of an expert panel on the use of bisphosphonates in multiple myeloma</a> (2009)</p><p/><p class=\"headingAnchor\" id=\"H1834792362\"><span class=\"h1\">United Kingdom</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ta510&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dPHQvjOmIcA9y05mmtmpE1D&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">National Institute for Health and Care Excellence (NICE): Technology appraisal guidance on daratumumab monotherapy for treating relapsed and refractory multiple myeloma</a> (2018)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ta505&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dMuC5uUWWZUUaQTzp9sz0yY&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">NICE: Technology appraisal guidance on ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma</a> (2018)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/bjh.14514/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKSBtjF4IFtG098sfOfLm7rGVdpvxeMcIafZY29KjWukew==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">UK Myeloma Forum (UKMF) and British Society for Haematology (BSH): Guidelines for screening and management of late and long-term consequences of myeloma and its treatment</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/bjh.14827/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKSBtjF4IFtG098sfOfLm7rGvg8m/8KJZk0M22xBRBNokQ==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">BSH: Guidelines for the use of imaging in the management of patients with myeloma</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ta311&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dM88+VT53ngNjb6K6/+AWPI&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">NICE: Technology appraisal guidance on bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation</a> (2014, reviewed 2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ta457&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dPapBgPeMacOssvCsnbfuCx&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">NICE: Technology appraisal guidance on carfilzomib for previously treated multiple myeloma</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ta491&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dOoLkBLf2bbSFL9KWObCdk+&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">NICE: Technology appraisal guidance on ibrutinib for treating Waldenstr&ouml;m's macroglobulinaemia</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ta427&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dNGio5+e61lbzU6ud5VWtYu&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">NICE: Technology appraisal guidance on pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ng35&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dMWqKrJTVjRbi+vCrik8fXm&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">NICE: Guideline on myeloma &ndash; Diagnosis and management</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ta380&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dOq79s6ELHGy2FfLf10GJf+&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">NICE: Technology appraisal guidance on panobinostat for treating multiple myeloma after at least 2 previous treatments</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ta228&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dMfw0Np4fwQNwpWOWcfNDv1&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">NICE: Technology appraisal guidance on bortezomib and thalidomide for the first-line treatment of multiple myeloma</a> (2011, reviewed 2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/bjh.13156/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKSBtjF4IFtG098sfOfLm7rG80uf5nRRXEt8uyqCDox+Bw==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">BSH: Guidelines on the diagnosis and investigation of AL amyloidosis</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/bjh.12760/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKSBtjF4IFtG098sfOfLm7rG8VIh+FLyQvmziSNvzryuHA==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">BSH: Guidelines on the diagnosis and management of Waldenstr&ouml;m macroglobulinaemia</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/bjh.13155/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKSBtjF4IFtG098sfOfLm7rGIKd9QnFzxFtpnAvTUTId5Q==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">BSH: Guidelines on the management of AL amyloidosis</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ta171&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dNurFzNHLW1MTSzTsz2/7nD&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">NICE: Technology appraisal guidance on lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy</a> (2009, updated 2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://academy.myeloma.org.uk/wp-content/uploads/sites/2/2014/08/ijlh-Maintenance.pdf&amp;token=xPAXNRnoPXshkZqQLw0uorMIqwb4F6+jLAD2j10Litkb/lqoNZNpBLf05Ir/UQ8K3JD+Xx0pBEkGbOK3pbVe0wRV7zzxfJkdOVnooNfJhBLkbzNF42bEWyCM7jVaN+0b&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">UKMF: Position statement on the use of consolidation and maintenance treatment in myeloma</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://academy.myeloma.org.uk/wp-content/uploads/sites/2/2014/08/ijlh12097.pdf&amp;token=rdrrm8Kze8stkf0t3cHdh8csmS1FqcLE0cqyP4miEAF+CDgLCcVEC23OwkJbawvjir2oMA2dwy/1kHtUmS+JIDx7X2aa8seG3IVCgpXNgB+vALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">UKMF: Position statement on the use of bendamustine in myeloma</a> (2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nice.org.uk/guidance/ta129&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dOavRdSn7E7c2ZBP8dwNtMG&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">NICE: Technology appraisal guidance on bortezomib monotherapy for relapsed multiple myeloma</a> (2007, reviewed 2012)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2011.08574.x/epdf&amp;token=ULEvSIaMcfDEBYpZuOiP1iExluGn4neiKZetd73LVHE1r5rjzHwnF8AHHIRy9+z8ulYA2Da69iY5FMQVPqL0neyGWXL2MrNSBmazC7rykIY=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">BSH and UKMF: Guidelines for supportive care in multiple myeloma</a> (2011)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2009.07807.x/epdf&amp;token=bqifQq2xvlVRlerBVZfx6yG3pWTaMc14aindqi2LPH/VOOXZP4qZ6dmMBGAoYfP9+ZCvBV6p2Pcug234RaqRKIm2wWV9aeKeCeNt3ZYT+W0=&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">UKMF and Nordic Myeloma Study Group (NMSG): Guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)</a> (2009)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.b-s-h.org.uk/guidelines/guidelines/diagnosis-and-management-of-solitary-plasmacytoma-of-bone-extramedullary-plasmacytoma-and-multiple-solitary-plasmacytomas/&amp;token=kiTgL6q1sQCbK/ZfA53rMDx50FWwOfrM27WHNB0ovvq2pCPAKdJ4Ya5JzcvIJoZ8nJ3pFqX+glkhX7COs6dK4rSriqQAV0faAO5B/YxS7eImG/EF437FsxCTBLXDXFUw7CqJG/vL5lOPMFf2G+2ztQ==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">BSH: Guidelines on the diagnosis and management of solitary plasmocytoma of bone and solitary extramedullary plasmacytoma</a> (2004, updated 2009)</p><p/><p class=\"headingAnchor\" id=\"H2263879996\"><span class=\"h1\">Australia</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://myeloma.org.au/wp-content/uploads/2017/10/MSAG-Clinical-Practice-Guideline-Myeloma-V4-March-2017.pdf&amp;token=Wg6ksdSuJffm7vfcSlEMGoKAVd8WiHrd2ov63bsEWOE6IbJyi6YfxKLVd0YNQ+dOfocEPFj4eDkSASlXLhws932hHnnCUeHOm4727Rod71llUcWF7iGwj0j4/qXZINwpbgwH2gQLNcGjYsvbXDVnpw==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">Medical Scientific Advisory Group to the Myeloma Foundation of Australia (MSAG MFA): Clinical practice guideline on multiple myeloma</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://myeloma.org.au/wp-content/uploads/2017/10/Bisphosphonate-guidelines-treatment-prevention-Lee-et-al-2017-IMJ.pdf&amp;token=pzSqBeOLYUjFvXLNmDfcH7VKtflZxjv0/JMct5Ep7aZ2WRIGMaC+Njolxd8jemtw5oyBdyzwNduqAWO6hPO74KHoCgfH1D5e5C9Y8us6VpBaLdwAsklp+aBh5GNGRUzQn21zRTGuSkQrK6zGnSoRbw==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">Royal Australasian College of Physicians (RACP): Position paper on bisphosphonate guidelines for treatment and prevention of myeloma bone disease</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://myeloma.org.au/wp-content/uploads/2017/10/WM_guidelines_FINAL.pdf&amp;token=Ta2Q2Ei3PwjZOv30SHlssW/RRez82BmTQ+Uuj58yubSfvKhEYdRBxabbWi2SS51tiS9CrtlIzSejYLF448e4syCjbfV86kwz8Bhw6pbZw7KvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">MSAG MFA: Clinical practice guideline on Waldenstr&ouml;m macroglobulinaemia</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://myeloma.org.au/wp-content/uploads/2017/10/Management-of-Systemic-AL-Amyloidosis.pdf&amp;token=biIeDZmrcfMZgteFqIYpEBnr41PyTzEQiuhb75Q3DNZfJZse7Rmi++3d/pKsMF/vLdrUWCCIjVvkrKFNkUFuktq/6o9cBohTJlKandWIeHHq3exzw+c1TP+/DDpOX10l&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">MSAG MFA: Clinical practice guideline on the management of systemic AL amyloidosis</a> (2015)</p><p/><p class=\"headingAnchor\" id=\"H17739140\"><span class=\"h1\">Japan</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>[In Japanese] <a href=\"http://www.jshem.or.jp/gui-hemali/table.html&amp;token=LUlre2Rk71Qupk7gX7fI260Ma1Vn9WFiR8gRcpawgbUVarQklQ6/6VvZxohxLp3G57kqR6mmDZ4h6sF+d/IZJg==&amp;TOPIC_ID=114824\" target=\"_blank\" class=\"external\">Japanese Society of Hematology (JSH): Clinical practice guidelines for hematological malignancies</a> (2013)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 114824 Version 1.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H4082612137\" id=\"outline-link-H4082612137\">Introduction</a></li><li><a href=\"#H2722319216\" id=\"outline-link-H2722319216\">International</a></li><li><a href=\"#H3121633521\" id=\"outline-link-H3121633521\">Canada</a></li><li><a href=\"#H1797798641\" id=\"outline-link-H1797798641\">United States</a></li><li><a href=\"#H1774363305\" id=\"outline-link-H1774363305\">Europe</a></li><li><a href=\"#H1834792362\" id=\"outline-link-H1834792362\">United Kingdom</a></li><li><a href=\"#H2263879996\" id=\"outline-link-H2263879996\">Australia</a></li><li><a href=\"#H17739140\" id=\"outline-link-H17739140\">Japan</a></li></ul></div>","javascript":null}